Skip to main content
. Author manuscript; available in PMC: 2013 Dec 7.
Published in final edited form as: J Thorac Cardiovasc Surg. 2012 Sep 29;144(6):10.1016/j.jtcvs.2012.08.064. doi: 10.1016/j.jtcvs.2012.08.064

FIGURE 3.

FIGURE 3

Group IIa secretory phospholipase A2 (sPLA2IIa) inhibition attenuates nuclear factor kappa-b (NF-κB) activity in all cell lines, with a variable effect on extracellular signal-regulated kinase (ERK) 1/2 activity. NF-κB attenuation does not correlate with sPLA2IIa expression level. Both H2009 and H358 (white bar graphs) are mutant p53 and demonstrate a more modest decrease in NF-κB activity (vc, vehicle control). Representative Western blots with corresponding densitometry, mean ± SEM, *P<.05, **P<.01, #P<.001, n =3–5.